(+)-[C-11]-cis-N-benzyl-normetazocine: A selective ligand for sigma receptors in vivo

John L. Musachio, Ursula Scheffel, Marigo Stathis, Hayden T. Ravert, William B. Mathews, Robert F. Dannals

Research output: Contribution to journalArticle

Abstract

The in vivo biodistribution profile of the novel sigma (σ) receptor ligand (+)-[C-11]-cis-N-benzyl-normetazocine ([C-11]-(+)-NBnNM) in mouse brain was examined. This radioligand displayed high brain uptake and a distribution consistent with the density of σ receptors. Brain radioactivity levels peaked at 15 min postinjection and were largely maintained (ca. 80% of maximal values) up to 90 min postinjection. Pretreatment with several different σ ligands (haloperidol, (+)-pentazocine, DuP 734, ifenprodil) effectively inhibited [C-11]-(+)-NBnNM binding in a dose-dependent manner in all brain regions. [C-11]-(+)-NBnNM binding sites were shown to be saturable with unlabeled (+)-NBnNM (ED50 = 0.02 mg/kg) and enantioselectively inhibited by the optical isomers of pentazocine. A blocking dose of the dopamine D2 antagonist spiperone (1 mg/kg) did not significantly inhibit [C-11]-(+)-NBnNM binding. Pretreatment with the phencyclidine (PCP) blocker 1-[1-(2-thienyl)cyclohexyl] piperidine (TCP) did not significantly alter total brain tissue radioactivity. Thus, [C-11]-(+)-NBnNM binds with high specificity and selectivity to σ receptors in vivo and offers excellent potential to study σ receptors in living human brain via positron emission tomography.

Original languageEnglish (US)
Pages (from-to)PL225-PL232
JournalLife Sciences
Volume55
Issue number11
DOIs
StatePublished - 1994

Keywords

  • carbon-11
  • positron emission tomography
  • sigma receptors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of '(+)-[C-11]-cis-N-benzyl-normetazocine: A selective ligand for sigma receptors in vivo'. Together they form a unique fingerprint.

  • Cite this